TD Cowen analyst Charles Rhyee raised the firm’s price target on McKesson (MCK) to $1,000 from $864 and keeps a Buy rating on the shares. The firm said they reported F2Q26 adj. EPS of $9.86 vs cons of $9.03, driven by strength in NA Pharma and benefiting from some 1x items.
Claim 70% Off TipRanks This Holiday Season
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis and maximize your portfolio's potential
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on MCK: